Acute myeloid leukaemia (AML), while relatively rare, is the most common form of acute leukaemia in adults and results in a poor 5-year overall survival (OS).1 Therefore, new effective treatments are highly sought after. In this article, some of the highlights of AML presented at the ASH 2024 meeting are discussed.
(BELG J HEMATOL 2025;16(1):19–22)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
